4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
SC 13G/A - Carmell Corp (0001842939) (Subject)
PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced the appointment of Ms. Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Mr. Rajiv Shukla continuing to serve as Executive Chairman of the Company. Kendra's appointment comes at a pivotal moment of growth for the Company. Since its business combination in July 2023, the Company has completed a pivot towards skincare, recruited a top-tier Scientific Advisory Board, developed and tested 12 skincare products aimed at retail and medspa use, scaled up in-house manufacturing and packagi
PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and co
RW - Carmell Corp (0001842939) (Filer)
424B3 - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
424B3 - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
424B3 - Carmell Corp (0001842939) (Filer)
10-Q - Carmell Corp (0001842939) (Filer)
424B3 - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
424B3 - Carmell Corp (0001842939) (Filer)
Board of Industry Leaders to Steer Strategic Growth as Blushington Aims to Award 130 Franchises by 2028 Blushington, the express luxury beauty franchise concept dedicated to making A-List beauty services accessible to all customers, today announced the formation of a National Advisory Board. This board will provide strategic guidance and support the company's ambitious plan to award 130 franchises by 2028. "We are delighted to bring together some of the most accomplished business leaders in beauty, franchising, commercial real estate, product development, and human capital solutions to provide strategic guidance and help increase the value of our business," said Natasha Cornstein, CEO of
PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced a strategic partnership with Ladies Playbook, an exclusive community dedicated to providing support, information, and the connections for an NFL family to thrive wherever their football career takes them. The NFL is the most valuable sports franchise in the world, with annual revenues approaching $20 billion from 32 teams, collectively worth approximately $160 billion, according to Statista. This partnership comes as the new NFL season kicks into full gear and as Carmell aims to accelerate the growth of it
PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced the appointment of Ms. Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Mr. Rajiv Shukla continuing to serve as Executive Chairman of the Company. Kendra's appointment comes at a pivotal moment of growth for the Company. Since its business combination in July 2023, the Company has completed a pivot towards skincare, recruited a top-tier Scientific Advisory Board, developed and tested 12 skincare products aimed at retail and medspa use, scaled up in-house manufacturing and packagi
PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of its previously announced private placement with new and existing investors (the "Private Placement"). The Company received gross proceeds from the Private Placement of $3 million, excluding offering expenses. The Company issued and sold an aggregate amount of 1,331,452 shares of its common stock upon the closing of the Private Placement at a price of $2.88 per share for the Company's Chief Executive Officer (which was the closing sale price of the Company's common stock on
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the "Private Placement"). The Chief Executive Officer of the Company participated in the Private Placement at a price of $2.88 per common share, which was the closing sale price of
PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable. "The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and continuing over Summer
PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and co
PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell" or the "Company"), today announced it will host an Investor Webinar titled "Unveiling the Secretome: On the Eve of Product Launch" on March 20, 2024 at 3:00 PM ET to discuss Carmell Secretome™, the biggest technological revolution in regenerative skin and haircare to the fast-growing ~$500 billion aesthetics industry. To register, click here. The event will feature Rajiv Shukla, Chairman & CEO of Carmell, joined by key opinion leaders (KOLs), Dr Gilles Spenlehauer, PhD (former Worldwide head of research for L'Oreal, the world's #1 cosmetics
PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell" or the "Company"), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.) product for commercial launch in March 2024. Additionally, the Company is in advanced stages of development and testing of 9 other skincare products anticipated to launch over Spring and Summer 2024. The Carmell skincare product portfolio: Carmell G.L.E.E. – limited edition exclusive product by invitation only. Launching in March 2024.Youth Restoring formula – daily cream to reduce the appearance of wrinkles and
PITTSBURGH, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a human biomaterials company ("Carmell"), today announced the addition of two independent directors to their Board. Scott Frisch currently serves as Chief Operating Officer and Chief Financial Officer of AARP. AARP is the nation's largest nonprofit, nonpartisan organization focused on issues affecting the more than 100 million people ages 50 and older. In this role, he leads AARP's operational and financial matters including human resources, information technology, real estate and facilities management, as well as data and analytics performance management. Previously, Mr. Frisch served as Managing Director at
- SEC Filing
Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results. Nucor reported quarterly earnings of $3.46 per share which missed the analyst consensus estimate of $3.65. Quarterly sales came in at $8.14 billion, missing the analyst consensus estimate of $8.26 billion, according to data from Benzinga Pro. Nucor shares tumbled 6.5% to $179.20 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Cyngn Inc. (NASDAQ:CYN) shares jumped 100% to $0.2419 after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to Joh
Gainers Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million. Macrogenics (NASDAQ:MGNX) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million. Curis (NASDAQ
Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the "Private Placement"). The Chief Executive Officer of the Company participated in the Private Placement at a price of $2.88 per common share, which was the closing sale price of its common stock on the Nasdaq Capital Market on A
Gainers Better Therapeutics (NASDAQ:BTTX) shares increased by 65.4% to $0.06 during Friday's regular session. The market value of their outstanding shares is at $3.1 million. Carmell (NASDAQ:CTCX) shares rose 38.52% to $3.2. The market value of their outstanding shares is at $73.8 million. P3 Health Partners (NASDAQ:PIII) stock rose 38.23% to $0.98. The market value of their outstanding shares is at $112.5 million. Akebia Therapeutics (NASDAQ:AKBA) shares rose 28.1% to $1.75. The market value of their outstanding shares is at $330.6 million. The company's, Q4 earnings came out yesterday. Acrivon Therapeutics (NASDAQ:ACRV) shares increased by 26.03% to $6.39. The market value of their ou
Shares of Freshpet, Inc. (NASDAQ:FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. Freshpet posted quarterly earnings of 31 cents per share, beating market estimates of 5 cents per share. The company’s quarterly sales came in at $215.42 million versus expectations of $204.36 million. Freshpet shares gained 15.5% to $106.29 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Akili, Inc. (NASDAQ:AKLI) shares jumped 126% to $0.5009 after the company reported positive results from Shionogi's Phase 3 clinical trial of localized version of Akili's EndeavorRx® for Pediatric ADHD patients in Japan. Z
Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell" or the "Company"), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.) product for commercial launch in March 2024. Additionally, the Company is in advanced stages of development and testing of 9 other skincare products anticipated to launch over Spring and Summer 2024. The Carmell skincare product portfolio: Carmell G.L.E.E. – limited edition exclusive product by invitation only. Launching in March 2024. Youth Restoring formula – daily cream to reduce the appearance of wrinkles and blemishes. Treatment Enhancing formula – fo
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares moved upwards by 33.2% to $0.48 during Tuesday's regular session. The current volume of 13.0 million shares is 535.8% of Inovio Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $128.2 million. NanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.74% to $1.52. Trading volume for this security as of 13:30 EST is 3.2 million, which is 213.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $72.3 million. Scinai Immunotherapeutics (NASDAQ:SCNI) shares increased by 21.21% to $0.8. T